Total trials
2,135
Active
474
Phase 3
82
Total enrollment
4,920,992
Pipeline matrix
Showing 40 of 182 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ketamine | — | — | 8 | ||||
| Normal saline | — | — | — | 6 | |||
| Propofol | — | 6 | |||||
| Ropivacaine | — | — | — | — | 3 | ||
| Tirzepatide | — | — | — | — | 2 | ||
| Metformin | — | — | — | — | 2 | ||
| Topiramate | — | — | — | — | — | 2 | |
| propranolol | — | — | — | — | 2 | ||
| Amiodarone | — | — | — | — | — | 1 | |
| Galcanezumab | — | — | — | — | — | 1 | |
| Erenumab 70 mg | — | — | — | — | — | 1 | |
| Eptinezumab | — | — | — | — | — | 1 | |
| Atogepant | — | — | — | — | — | 1 | |
| Amitriptyline | — | — | — | — | — | 1 | |
| Nortriptyline | — | — | — | — | — | 1 | |
| Verapamil SR 120 mg | — | — | — | — | — | 1 | |
| Candesartan | — | — | — | — | — | 1 | |
| GLP-1A | — | — | — | — | — | 1 | |
| Anti-convulsant medications | — | — | — | — | — | 1 | |
| Anti-depressant medications | — | — | — | — | — | 1 | |
| OnabotulinumtoxinA 100 UNT [Botox] | — | — | — | — | — | 1 | |
| Sodium Chloride 0.9% for Injection, Preservative Free | — | — | — | — | — | 1 | |
| Low sodium oxybate | — | — | — | — | — | 1 | |
| Sulfadoxine pyrimethamine + Amodiaquine | — | — | — | — | — | 1 | |
| Dihydroartemisinin Piperaquine | — | — | — | — | — | 1 | |
| Dihydroartemisinin Piperaquine Placebo | — | — | — | — | — | 1 | |
| Sulfadoxine pyrimethamine + Amodiaquine placebo | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | 8 | ||||
| Pioglitazone | — | — | — | 5 | |||
| N-acetylcysteine | — | — | — | — | 3 | ||
| Nebivolol | — | — | — | — | 2 | ||
| Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. | — | — | — | — | — | 1 | |
| Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days | — | — | — | — | — | 1 | |
| N acetyl cysteine | — | — | — | — | — | 1 | |
| Standardized seizure protocol | — | — | — | — | — | 1 | |
| Conventional seizure protocol | — | — | — | — | — | 1 | |
| Tizanidine | — | — | — | — | — | 1 | |
| Cilostazol 100 mg | — | — | — | — | — | 1 | |
| Ripasudil | — | — | — | — | — | 1 | |
| Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg | — | — | — | — | — | 1 |
142 more active programs hidden
Next readouts
- 2023-06-20
- 2025-02
- 2025-04-03
- 2025-05-16
- 2025-06-20
- 2025-08
- 2025-08-15
- 2025-08-15
- 2025-11-30
- 2026-01-31
Top conditions
- Breast Cancer57
- Obesity55
- Depression53
- Pain39
- Autism Spectrum Disorder34
- Chronic Pain31
- Anxiety31
- Insulin Resistance26
Frequently asked questions about Stanford University
- How many clinical trials does Stanford University have on ClinicalTrials.gov?
- Stanford University is listed as the lead sponsor on 2,135 clinical trials in ClinicalTrials.gov, 474 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Stanford University's trials are in Phase 3?
- 82 of Stanford University's trials are in Phase 3, spread across 182 active drug programs.
- What therapeutic areas does Stanford University focus on?
- Stanford University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Obesity, Depression, Pain, Autism Spectrum Disorder.
- When are Stanford University's next clinical trial readouts?
- Stanford University has 10 upcoming primary-completion readouts tracked here; the soonest is “CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies”, expected around 2023-06-20.